Enhanced Nasal Drug Administration to Brain by a New Nanotechnology: The Phospholipid Magnesome

Touitou Elka, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research


Life Science & Biotechnology, Nanotechnology

Technology Keywords:

Nasal delivery, CNS, quick onset,

 peptides ,brain

Development Stage:

Formulations, results in animal

Patent Status:



We have designed and developed formulations based on a new nano-vesicular carrier containing Magnesium- the Phospholipid Magnesome.  This drug delivery nanotechnology was tested in animal models. Results show enhanced efficacy versus controls.

Key Features

  • Improved delivery into the brain – quick onset
  • Better bioavailability by nasal route than by oral or subcutaneous routes
  • Particularly important in crisis management of  pain,  Parkinson rigidity, multiple sclerosis, Alzheimer, insomnia, glioma, sleepiness (EDS), epileptic seizures, hyperglycaemia, hypoglycaemia, hot flushes, emesis,
  • Carrier ingredients already have FDA approval.
  • Increase patient compliance - needle-free alternative for delivering drugs for acute and chronic conditions, allowing self-medication.

Contact for more information:

Shani Bullock
VP, Business Development, Healthcare
Contact ME: